Global Recombinant Humanized Bisspecific Antibody 麻豆原创 Growth 2024-2030

Publication ID:

LPI11244284

Publication Date:

November 11, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Recombinant humanized bisspecific antibody used CTLA-4 single domain antibody with significantly improved safety. Fusion with PD-L1 antibody to form bispecific antibody; It can target the tumor microenvironment enriched with high expression of PD-L1 and clear Treg.
The global Recombinant Humanized Bisspecific Antibody market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淩ecombinant Humanized Bisspecific Antibody Industry Forecast鈥� looks at past sales and reviews total world Recombinant Humanized Bisspecific Antibody sales in 2023, providing a comprehensive analysis by region and market sector of projected Recombinant Humanized Bisspecific Antibody sales for 2024 through 2030. With Recombinant Humanized Bisspecific Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Humanized Bisspecific Antibody industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Humanized Bisspecific Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Humanized Bisspecific Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Recombinant Humanized Bisspecific Antibody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Humanized Bisspecific Antibody and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Humanized Bisspecific Antibody.
United States market for Recombinant Humanized Bisspecific Antibody is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Recombinant Humanized Bisspecific Antibody is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Recombinant Humanized Bisspecific Antibody is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Recombinant Humanized Bisspecific Antibody players cover Sunshine Guojian Pharmaceutical, Milestone (Shanghai) Biological Science & Technology, Akeso, Inc, Alphamab Oncology, Detai Bio-Tech, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Humanized Bisspecific Antibody market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
With Fc Area
No Fc Area
Segmentation by Application:
Breast Cancer
Stomach Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sunshine Guojian Pharmaceutical
Milestone (Shanghai) Biological Science & Technology
Akeso, Inc
Alphamab Oncology
Detai Bio-Tech
Junshi Biosciences
CSPC Pharmaceutical Group
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Humanized Bisspecific Antibody market?
What factors are driving Recombinant Humanized Bisspecific Antibody market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Humanized Bisspecific Antibody market opportunities vary by end market size?
How does Recombinant Humanized Bisspecific Antibody break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Recombinant Humanized Bisspecific Antibody Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Recombinant Humanized Bisspecific Antibody by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Recombinant Humanized Bisspecific Antibody by Country/Region, 2019, 2023 & 2030
2.2 Recombinant Humanized Bisspecific Antibody Segment by Type
2.2.1 With Fc Area
2.2.2 No Fc Area
2.3 Recombinant Humanized Bisspecific Antibody Sales by Type
2.3.1 Global Recombinant Humanized Bisspecific Antibody Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Recombinant Humanized Bisspecific Antibody Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Recombinant Humanized Bisspecific Antibody Sale Price by Type (2019-2024)
2.4 Recombinant Humanized Bisspecific Antibody Segment by Application
2.4.1 Breast Cancer
2.4.2 Stomach Cancer
2.4.3 Other
2.5 Recombinant Humanized Bisspecific Antibody Sales by Application
2.5.1 Global Recombinant Humanized Bisspecific Antibody Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Recombinant Humanized Bisspecific Antibody Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Recombinant Humanized Bisspecific Antibody Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Recombinant Humanized Bisspecific Antibody Breakdown Data by Company
3.1.1 Global Recombinant Humanized Bisspecific Antibody Annual Sales by Company (2019-2024)
3.1.2 Global Recombinant Humanized Bisspecific Antibody Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Recombinant Humanized Bisspecific Antibody Annual Revenue by Company (2019-2024)
3.2.1 Global Recombinant Humanized Bisspecific Antibody Revenue by Company (2019-2024)
3.2.2 Global Recombinant Humanized Bisspecific Antibody Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Recombinant Humanized Bisspecific Antibody Sale Price by Company
3.4 Key Manufacturers Recombinant Humanized Bisspecific Antibody Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Humanized Bisspecific Antibody Product Location Distribution
3.4.2 Players Recombinant Humanized Bisspecific Antibody Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Recombinant Humanized Bisspecific Antibody by Geographic Region
4.1 World Historic Recombinant Humanized Bisspecific Antibody 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Recombinant Humanized Bisspecific Antibody Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Recombinant Humanized Bisspecific Antibody Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Recombinant Humanized Bisspecific Antibody 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Recombinant Humanized Bisspecific Antibody Annual Sales by Country/Region (2019-2024)
4.2.2 Global Recombinant Humanized Bisspecific Antibody Annual Revenue by Country/Region (2019-2024)
4.3 Americas Recombinant Humanized Bisspecific Antibody Sales Growth
4.4 APAC Recombinant Humanized Bisspecific Antibody Sales Growth
4.5 Europe Recombinant Humanized Bisspecific Antibody Sales Growth
4.6 Middle East & Africa Recombinant Humanized Bisspecific Antibody Sales Growth
5 Americas
5.1 Americas Recombinant Humanized Bisspecific Antibody Sales by Country
5.1.1 Americas Recombinant Humanized Bisspecific Antibody Sales by Country (2019-2024)
5.1.2 Americas Recombinant Humanized Bisspecific Antibody Revenue by Country (2019-2024)
5.2 Americas Recombinant Humanized Bisspecific Antibody Sales by Type (2019-2024)
5.3 Americas Recombinant Humanized Bisspecific Antibody Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Humanized Bisspecific Antibody Sales by Region
6.1.1 APAC Recombinant Humanized Bisspecific Antibody Sales by Region (2019-2024)
6.1.2 APAC Recombinant Humanized Bisspecific Antibody Revenue by Region (2019-2024)
6.2 APAC Recombinant Humanized Bisspecific Antibody Sales by Type (2019-2024)
6.3 APAC Recombinant Humanized Bisspecific Antibody Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Recombinant Humanized Bisspecific Antibody by Country
7.1.1 Europe Recombinant Humanized Bisspecific Antibody Sales by Country (2019-2024)
7.1.2 Europe Recombinant Humanized Bisspecific Antibody Revenue by Country (2019-2024)
7.2 Europe Recombinant Humanized Bisspecific Antibody Sales by Type (2019-2024)
7.3 Europe Recombinant Humanized Bisspecific Antibody Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant Humanized Bisspecific Antibody by Country
8.1.1 Middle East & Africa Recombinant Humanized Bisspecific Antibody Sales by Country (2019-2024)
8.1.2 Middle East & Africa Recombinant Humanized Bisspecific Antibody Revenue by Country (2019-2024)
8.2 Middle East & Africa Recombinant Humanized Bisspecific Antibody Sales by Type (2019-2024)
8.3 Middle East & Africa Recombinant Humanized Bisspecific Antibody Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Humanized Bisspecific Antibody
10.3 Manufacturing Process Analysis of Recombinant Humanized Bisspecific Antibody
10.4 Industry Chain Structure of Recombinant Humanized Bisspecific Antibody
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Humanized Bisspecific Antibody Distributors
11.3 Recombinant Humanized Bisspecific Antibody Customer
12 World Forecast Review for Recombinant Humanized Bisspecific Antibody by Geographic Region
12.1 Global Recombinant Humanized Bisspecific Antibody 麻豆原创 Size Forecast by Region
12.1.1 Global Recombinant Humanized Bisspecific Antibody Forecast by Region (2025-2030)
12.1.2 Global Recombinant Humanized Bisspecific Antibody Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Recombinant Humanized Bisspecific Antibody Forecast by Type (2025-2030)
12.7 Global Recombinant Humanized Bisspecific Antibody Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Sunshine Guojian Pharmaceutical
13.1.1 Sunshine Guojian Pharmaceutical Company Information
13.1.2 Sunshine Guojian Pharmaceutical Recombinant Humanized Bisspecific Antibody Product Portfolios and Specifications
13.1.3 Sunshine Guojian Pharmaceutical Recombinant Humanized Bisspecific Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Sunshine Guojian Pharmaceutical Main Business Overview
13.1.5 Sunshine Guojian Pharmaceutical Latest Developments
13.2 Milestone (Shanghai) Biological Science & Technology
13.2.1 Milestone (Shanghai) Biological Science & Technology Company Information
13.2.2 Milestone (Shanghai) Biological Science & Technology Recombinant Humanized Bisspecific Antibody Product Portfolios and Specifications
13.2.3 Milestone (Shanghai) Biological Science & Technology Recombinant Humanized Bisspecific Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Milestone (Shanghai) Biological Science & Technology Main Business Overview
13.2.5 Milestone (Shanghai) Biological Science & Technology Latest Developments
13.3 Akeso, Inc
13.3.1 Akeso, Inc Company Information
13.3.2 Akeso, Inc Recombinant Humanized Bisspecific Antibody Product Portfolios and Specifications
13.3.3 Akeso, Inc Recombinant Humanized Bisspecific Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Akeso, Inc Main Business Overview
13.3.5 Akeso, Inc Latest Developments
13.4 Alphamab Oncology
13.4.1 Alphamab Oncology Company Information
13.4.2 Alphamab Oncology Recombinant Humanized Bisspecific Antibody Product Portfolios and Specifications
13.4.3 Alphamab Oncology Recombinant Humanized Bisspecific Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Alphamab Oncology Main Business Overview
13.4.5 Alphamab Oncology Latest Developments
13.5 Detai Bio-Tech
13.5.1 Detai Bio-Tech Company Information
13.5.2 Detai Bio-Tech Recombinant Humanized Bisspecific Antibody Product Portfolios and Specifications
13.5.3 Detai Bio-Tech Recombinant Humanized Bisspecific Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Detai Bio-Tech Main Business Overview
13.5.5 Detai Bio-Tech Latest Developments
13.6 Junshi Biosciences
13.6.1 Junshi Biosciences Company Information
13.6.2 Junshi Biosciences Recombinant Humanized Bisspecific Antibody Product Portfolios and Specifications
13.6.3 Junshi Biosciences Recombinant Humanized Bisspecific Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Junshi Biosciences Main Business Overview
13.6.5 Junshi Biosciences Latest Developments
13.7 CSPC Pharmaceutical Group
13.7.1 CSPC Pharmaceutical Group Company Information
13.7.2 CSPC Pharmaceutical Group Recombinant Humanized Bisspecific Antibody Product Portfolios and Specifications
13.7.3 CSPC Pharmaceutical Group Recombinant Humanized Bisspecific Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 CSPC Pharmaceutical Group Main Business Overview
13.7.5 CSPC Pharmaceutical Group Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.